



# LungTraX™ Platform



The LungTraX Platform offers a comprehensive solution to enhance and expand your Zephyr® Valve program. This PACS-integrated system facilitates automated patient identification, collaborative workup management, and treatment planning with StratX® Reports—all within a single web-based platform.

## LungTraX Connect

LungTraX Connect Software enables a streamlined, efficient, and collaborative workup process to allow more time for delivering valuable care to patients.

### Key Features

#### 1. PACS Integration

- LungTraX Connect Software leverages an existing partnership with Ambra® Health to offer a seamless PACS integrated CT scan upload solution, enabling the direct transfer of CT scans for StratX Lung Analysis Reports.



#### 2. Protected Health Information (PHI) Enabled

- LungTraX Connect Software automates the retrieval of patient name and date-of-birth directly from the CT scan to display in the Case List in a secure and HIPAA compliant manner. There is no need to keep track of patient IDs in a separate document.

#### 3. Collaborative Patient Management Tools

- The easy-to-use workup test tracker, along with the open notes functionality, empowers your team by providing a way to visualize the next steps required in determining patient candidacy for Zephyr® Valves.

#### 4. Serves as the Connection-Point for Additional Integration Tools

# LungTraX™ Detect CT

LungTraX Detect CT automates the identification of underdiagnosed patients with severe COPD/emphysema in a way that seamlessly integrates into your Zephyr® Valve program workflow.

## Key Features

### 1. Automated Patient Identification\*

- Prospectively analyzes non-contrast chest CTs to identify patients within your hospital who have radiographically-significant emphysema.
- LungTraX Detect found between 10.5% to 18% of lung cancer screening CT scans had high level of emphysema.

### 2. Easy-to-Use Patient Management Tools

- Protected health information (PHI) enabled web portal provides tools to organize and manage patient candidates for Zephyr Valve treatment.
- Track PFT, comorbidity, smoking status, and access ordering physician information for easy outreach.

### 3. LungTraX Portal Integration

- Integration into the LungTraX Portal makes it easy to request StratX® Lung Analysis Reports and seamlessly transition a patient into the Zephyr Valve workup process.

\* Pulmonx's LungTraX Detect CT and StratX Reports help present information from CT scans analyzed by FDA-cleared software (Thirona's LungQ, K232412) for quantitative assessment of lung structure and function to support clinical decision making, diagnosis and follow-up. LungTraX Detect CT assists healthcare providers with visualizing this LungQ data, which may suggest the presence of emphysema. Refer to Thirona's indications for use here: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K232412>

## LungTraX® Platform

StratX® Report Patient List

Detect CT Patient List

## FILTER CASES

Apply

Clear

Accession Number

Requesting Physician

MRN

Scan Date From

Scan Date To

-910 HU

-950 HU

Health Status

- ☐ PFT
- ☐ No Comorbidities
- ☐ Non-Smoking

Status

☐ All

## Download Selected

	Name	DOB	MRN	Requesting Physician	Accession Number	Scan Date	Health Check			HU Values		Status	Notes
							PFT	No Comorbidities	Non-Smoking	910 HU	950 HU		
<input type="checkbox"/>	T. Hoffmeister	1964-Sep-11	1234567	Long	01234	2023-May-15	---	---	---	55	33	Not Yet Contacted	
<input type="checkbox"/>	K. Vance	1956-Apr-01	1234567	Radha	01234	2023-May-15	✓	✓	✓	60	30	Agreed	
<input type="checkbox"/>	B. Bishop	1970-Jan-06	1234567	French	01234	2023-May-15	✓	✓	✗	70	40	Pending Response	
<input type="checkbox"/>	M. Young	1963-Aug-27	1234567	Maroney	01234	2023-May-15	✗	✓	✗	55	35	Not Yet Contacted	
<input type="checkbox"/>	K. Holzer	1967-Dec-11	1234567	Long	01234	2023-May-15	✓	✓	✓	70	35	Pending Response	

LungTraX Detect CT provides an easy-to-use Health Check feature which allows your team to see whether a patient meets additional Zephyr Valve treatment criteria

LungTraX Detect CT's integration with the LungTraX Platform enables users to send the patient's CT scan for a full StratX Report with the "Send to StratX" button

Destruction score settings are customizable for users to tailor the minimum level of destruction required for patients to be displayed on the Detect CT Patient List

## Detect CT Threshold

910 HU | 50 %

950 HU | 30 %

Set to Default


The software will identify CT scans with one or more lobes that meet the HU threshold specified above. Adjusting the threshold will affect all future CT scans analyzed by the software. Previously identified CT scans will remain in the patient list.

Confirm

Cancel

Destruction score settings are configurable for -910 HU and -950 HU

## Presence of Emphysema in the National Lung Cancer Screening Trial<sup>1</sup>



### Presence of Valve-eligible Emphysema in a Pulmonx LungTraX™ Detect Pilot<sup>2</sup> Pulmonx found:

Center	LDCTs Analyzed	Valve-eligible Emphysema (%)
Center 1	256	10.5%
Center 2	275	18.1%
Center 3	609	15.2%

Feature	Standard LungTraX Platform	LungTraX Connect	LungTraX Detect CT
Manual CT upload	✓	✓	✓
Access to StratX baseline and post-treatment reports	✓	✓	✓
Access to basic web portal	✓		
PACS-integrated CT transfer for baseline reports		✓	✓
PHI-enabled web portal		✓	✓
Collaborative patient management tool		✓	✓
Upgradeable for future connected products and services		✓	LungTraX Connect subscription required
CT-based population screening			✓

1. Pinsky PF, Lynch DA, Gierada DS. Incidental Findings on Low-Dose CT Scan Lung Cancer Screenings and Deaths From Respiratory Diseases. Chest. 2022;161(4):1092-1100.

2. Pulmonx data on file. Valve-eligible emphysema defined as at least one lobe with emphysema destruction of  $\geq 45\%$  at  $-910\text{HU}$  OR  $\geq 25\%$  at  $-950\text{HU}$

**Important Safety Information:** The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone; or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, lobectomy, or pleurodesis on the target lung side; Congestive heart failure or recent myocardial infarction; FEV1  $<15\%$  of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

**Caution:** Federal law restricts this device to sale by or on the order of a physician.

© 2025 Pulmonx Corporation or its affiliates. All rights reserved.

All trademarks herein are property of Pulmonx Corporation and its affiliates.

The Ambra trademark is property of Ambra Health.

US-EN-2334-v5

